PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AI twice as accurate as a biopsy when grading severity of sarcomas

The new AI model could potentially be applied to other cancers.

New research from the Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust has revealed that artificial intelligence (AI) could be twice as accurate at grading the aggressiveness of some sarcomas as a biopsy.

The new AI algorithm could speed up the diagnosis of sarcoma patients and could potentially be applied to other cancers.

A biopsy, which is currently standard practice, is an invasive medical procedure that involves taking a small sample of body tissue for examination.

Around 4,295 people in England are diagnosed every year with soft tissue sarcomas, a rare type of cancer that develops in the connective tissues in the body, including fat, muscles and blood.

With over 50 forms of the condition, the RADSARC-R study analysed the CT scans of 170 patients treated at The Royal Marsden, with two common forms of a rare soft tissue sarcoma that develops in the back of the abdomen: retroperitoneal sarcoma – leiomyosarcoma and liposarcoma.

After producing an AI algorithm, researchers tested it on 90 patients across Europe and the US, using a technique called radiomics to extract information about patients’ diseases from medical images.

Results showed that the model accurately graded the aggressiveness of 82% of the tumours, compared to 44% which were accurately graded using biopsies, and accurately predicted the disease type of 84% of the sarcomas tested, compared to radiologists who could not diagnose 35% of the cases.

As well as speeding up diagnosis, the AI technology could improve the management of the disease and its outcomes and could spare low-risk patients from unnecessary treatments, scans and hospital visits.

“In the next phase… we will test this model in clinic on patients with potential retroperitoneal sarcomas to see if it can accurately characterise their disease and measure the performance of the technology over time,” said Dr Amani Arthur, clinical research fellow, ICR, and registrar, The Royal Marsden NHS Foundation Trust.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026